CIK 0001764013 · Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832771572
- Phone
- 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- 4 Grant or award Chief Medical Officer acquired 101,574 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 88,878 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 265,820 shares (grant or award)
- 4 Grant or award Director acquired 16,188 shares (grant or award)
- 4 Grant or award Director acquired 16,188 shares (grant or award)
- 4 Grant or award Director acquired 16,188 shares (grant or award)
- 4 Grant or award Director acquired 16,188 shares (grant or award)
- 4 Grant or award Director acquired 199,365 shares (grant or award)
- 4 Planned sale Director sold 8,000 shares at an average $19.60 ($156,769)
- 4 Open-market sale Chief Medical Officer sold 2,055 shares at $20.86 ($42,867)
- 4 Open-market sale Chief Financial Officer sold 2,814 shares at $20.86 ($58,700)
- 4 Open-market sale Chief Executive Officer sold 15,439 shares at $20.86 ($322,058)
- 4 Open-market sale Chief Technology Officer sold 2,195 shares at $23.59 ($51,780)
- 4 Open-market sale Chief Medical Officer sold 2,657 shares at $23.59 ($62,679)
- 4 Open-market sale Chief Medical Officer sold 2,383 shares at an average $23.83 ($56,782)
- 4 Open-market sale Chief Financial Officer sold 2,298 shares at an average $23.83 ($54,757)
- 4 Open-market sale Chief Executive Officer sold 8,767 shares at an average $23.83 ($208,900)
- 4 Open-market buy Director bought 16,845,010 shares at $20.00 ($336,900,200)
- 4 Open-market sale Chief Financial Officer sold 4,105 shares at $24.10 ($98,931)
- 4 Open-market sale Chief Executive Officer sold 5,105 shares at $24.10 ($123,031)
Page 5 of 18 · 360 filings